Home/Pipeline/RNA Editing Portfolio

RNA Editing Portfolio

Undisclosed Genetic Targets

ResearchDiscovery

Key Facts

Indication
Undisclosed Genetic Targets
Phase
Research
Status
Discovery
Company

About WaVe Life Sciences

Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Its core strategy is built on the PRISM® platform, a toolkit for designing and developing stereopure oligonucleotides, including RNA editing and silencing therapies. The company is rapidly advancing a diversified pipeline, with key programs like WVE-006 for Alpha-1 antitrypsin deficiency and WVE-007 (INHBE siRNA) for obesity generating significant clinical interest. Wave is strategically positioning itself at the forefront of next-generation genetic medicines.

View full company profile